The Female Health Company Addresses Netherlands House of Representatives

Role of Business/Female Health Company in Improving Sexual and Reproductive Health


CHICAGO, April 18, 2016 (GLOBE NEWSWIRE) -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced that on March 18, Denise van Dijk, FHC’s Director of Global Market Development, was one of three corporate speakers to address the House of Representatives in the Netherlands.  

Along with representatives from Heineken N.V. and Philips N.V., Ms. van Dijk spoke on the role corporations can play in improving Sexual and Reproductive Health and Rights and, in particular, on the worldwide role of The Female Health Company. “Investing in the FC2 Female Condom by governments and large global donors in the public sector means women’s empowerment and provides a return on investment for overall economic growth in those respective countries. A rights-based product such as FC2 is the result of the most interesting business model: one based on shared values. Profit and social impact are not mutually exclusive; instead, the combination provides a profitable and sustainable business model while positively impacting lives. When a solution makes profit it becomes self-sustaining, leading to an increase in scale and impact,” van Dijk said. The Female Health Company has long engaged with NGOs, governments, and companies through multiple public private partnerships based on a shared value business model.

An important step forward in changing the field of donors and international relations and development, the session’s audience comprised politicians, key players in the (Dutch) NGO-world, and individuals representing the business world.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.


            

Contact Data